MIRA Pharmaceuticals to acquire SKNY; combined enterprise value over $60M

MIRA PHARMACEUTICALS, INC.

Board unanimously approved definitive agreement to acquire SKNY on April 30, 2025.
Third-party valuation assigned SKNY enterprise value of ~$30.5M; MIRA ~$30M.
SKNY to contribute $5M in assets or cash at closing with no contingencies.
Combined enterprise value exceeds $60M, creating a broader platform targeting obesity and nicotine dependence.
MIRA preparing to file proxy statement to seek shareholder approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.